R&D channel feed

That biotech uni­corn you (pick love or hate) just spot­light­ed some in­trigu­ing mouse (yes) da­ta on a triple mR­NA can­cer ther­a­py

7 years ago
Discovery

No­var­tis lays out block­buster launch­es for 2018-2020, with sur­pris­ing in­clu­sion of Kym­ri­ah

7 years ago

J&J scores an­oth­er PhI­II win for Er­lea­da as it con­tin­ues to build a block­buster fran­chise

7 years ago

Hop­ing to brake a slow crash, Aduro's Stephen Isaacs hits the re­set but­ton, ax­ing staff in re­or­ga­ni­za­tion

7 years ago
People

Roche pulls an­oth­er ma­jor piece out of the wob­bly Alzheimer's jen­ga, shut­ter­ing crenezum­ab PhI­I­Is

7 years ago

Take­da claims PhI­II suc­cess in dengue vac­cine months af­ter Deng­vax­ia im­plo­sion for ri­val Sanofi

7 years ago

As Pfiz­er kills failed PhI­II pro­grams for Baven­cio, where do they go from here in R&D?

7 years ago
Bioregnum
Opinion

Pfiz­er and Lil­ly's tanezum­ab large­ly makes the ef­fi­ca­cy cut in sec­ond PhI­II study, but safe­ty is­sues con­tin­ue to blight an­ti-NGF drug

7 years ago

The next 5 years: High­er R&D pro­duc­tiv­i­ty is here to stay, emerg­ing biotechs and new tech will have a big im­pact. But what about pric­ing?

7 years ago
Startups
Pharma

Af­ter se­cur­ing quick OK for PNH pa­tients, Alex­ion's Ul­tomiris suc­ceeds in aHUS piv­otal study

7 years ago

Glob­al fund­ing for ne­glect­ed dis­ease R&D hit record high in 2017 — with meaty con­tri­bu­tions by UK, EC, In­dia and Ger­many

7 years ago

UK looks to en­sure phar­ma sub­mis­sions can con­tin­ue un­der no deal Brex­it

7 years ago
Pharma

Af­ter kick­back from the FDA, Bris­tol-My­ers yanks its Op­di­vo/Yer­voy BLA for high TMB ap­proach to lung can­cer

7 years ago

What’s up with all the buzz about Gilead’s PhI­II NASH drug selon­sert­ib?

7 years ago

FDA forces trou­bled Ad­vax­is to halt en­roll­ment on its PhI­II study for lead drug ax­al­imo­gene

7 years ago

Mi­cro­bio­me test mak­er uBio­me cuts 55 jobs to sharp­en fo­cus on drugs, part­ner­ships — CN­BC

7 years ago
Pharma

Mi­cro­bio­me, in­flam­ma­tion and mu­ta­tions: US re­searchers win £60M in Can­cer Re­search UK grants to lead 'grand chal­lenges'

7 years ago

Au­rinia eye drug falls short in im­prov­ing tol­er­a­bil­i­ty ver­sus Resta­sis, but beats on ef­fi­ca­cy

7 years ago

Ab­b­Vie, J&J con­cede a fail­ure for block­buster Im­bru­vi­ca in their PhI­II shot at pan­cre­at­ic can­cer

7 years ago

Safe­ty con­cerns lead to a split FDA pan­el vote on Sanofi/Lex­i­con di­a­betes drug

7 years ago
Pharma

Lil­ly's ap­proved can­cer drug Lartru­vo fails con­fir­ma­to­ry study, set­ting the stage for with­draw­al of reg­u­la­to­ry en­dorse­ment

7 years ago

Im­munomedics must en­dure an­oth­er de­lay as FDA re­jects can­cer drug cit­ing man­u­fac­tur­ing is­sues

7 years ago

Scoop: For­ma ax­es dis­cov­ery bi­ol­o­gy team as part of a broad­er re­or­ga­ni­za­tion

7 years ago
Pharma

Zaf­gen has some­thing to cheer as di­a­betes drug makes the cut in PhII study

7 years ago
First page Previous page 254255256257258259260 Next page Last page
A service from the Financial Times